Literature DB >> 24442086

Comparison of 3 severity criteria for Clostridium difficile infection.

Angela Gomez-Simmonds1, Christine J Kubin, E Yoko Furuya.   

Abstract

Effective severity criteria are needed to guide management of Clostridium difficile infection (CDI). In this retrospective study, outcomes were compared between patients with mild-moderate versus severe CDI according to 3 different severity criteria: those included in the 2010 Society for Healthcare Epidemiology of America/Infectious Diseases Society of America guidelines, those from a recent clinical trial, and our hospital-specific guidelines.

Entities:  

Mesh：

Year:  2013        PMID： 24442086      PMCID： PMC4791954          DOI： 10.1086/674851

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  9 in total

1.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

2.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

Review 3.  Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system.

Authors:  Jaime Belmares; Dale N Gerding; Jorge P Parada; Scott Miskevics; Frances Weaver; Stuart Johnson
Journal:  J Infect       Date:  2007-11-05       Impact factor: 6.072

Review 4.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

5.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors:  Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

7.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

8.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

Authors:  Fred A Zar; Srinivasa R Bakkanagari; K M L S T Moorthi; Melinda B Davis
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

Review 9.  Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review.

Authors:  M G Bloomfield; J C Sherwin; E Gkrania-Klotsas
Journal:  J Hosp Infect       Date:  2012-06-22       Impact factor: 3.926
  9 in total
  7 in total

1.  Severe Clostridium difficile infection: incidence and risk factors at a tertiary care university hospital in Vienna, Austria.

Authors:  Peter Starzengruber; Luigi Segagni Lusignani; Thomas Wrba; Dieter Mitteregger; Alexander Indra; Wolfgang Graninger; Elisabeth Presterl; Magda Diab-Elschahawi
Journal:  Wien Klin Wochenschr       Date:  2014-06-06       Impact factor: 1.704

2.  Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study.

Authors:  K Kobayashi; N Sekiya; Y Ainoda; H Kurai; A Imamura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-02       Impact factor: 3.267

3.  Predictors of Mortality Among a National Cohort of Veterans With Recurrent Clostridium difficile Infection.

Authors:  Haley J Appaneal; Aisling R Caffrey; Maya Beganovic; Sanja Avramovic; Kerry L LaPlante
Journal:  Open Forum Infect Dis       Date:  2018-07-19       Impact factor: 3.835

Review 4.  A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management.

Authors:  Csaba Fehér; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-07-28

5.  Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.

Authors:  Richard L Hengel; Timothy E Ritter; Ramesh V Nathan; Lucinda J Van Anglen; Claudia P Schroeder; Ryan J Dillon; Stephen W Marcella; Kevin W Garey
Journal:  Open Forum Infect Dis       Date:  2020-03-19       Impact factor: 3.835

6.  Risk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study.

Authors:  Hsiu-Yin Chiang; Han-Chun Huang; Chih-Wei Chung; Yi-Chun Yeh; Yi-Chin Chen; Ni Tien; Hsiu-Shan Lin; Mao-Wang Ho; Chin-Chi Kuo
Journal:  Antimicrob Resist Infect Control       Date:  2019-11-12       Impact factor: 4.887

7.  External validation of clinical prediction rules for complications and mortality following Clostridioides difficile infection.

Authors:  Catherine Beauregard-Paultre; Claire Nour Abou Chakra; Allison McGeer; Annie-Claude Labbé; Andrew E Simor; Wayne Gold; Matthew P Muller; Jeff Powis; Kevin Katz; Suzanne M Cadarette; Jacques Pépin; Louis Valiquette
Journal:  PLoS One       Date:  2019-12-17       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.